E
ENB Therapeutics
ENB Therapeutics is developing therapies to break barriers that prevent the majority of patients from responding to immunotherapy agents
About ENB Therapeutics
ENB Therapeutics is a clinical-stage biopharmaceutical company focused on addressing the significant challenge of drug resistance in cancer therapy. The firm was co-founded by Sumant Ramachandra, a seasoned pharmaceutical executive with experience at companies like Pfizer and Baxter, and Zachary Hornby. Ramachandra's background in drug development and corporate strategy, combined with Hornby's expertise in business development and operations, provided the foundational leadership for the company's mission. The company's core focus is the development of treatments that can overcome resistance to immunotherapy, a problem observed in a substantial portion of cancer patients. ENB Therapeutics operates within the oncology market, specifically targeting the multi-billion dollar immunotherapy sector. Its business model centers on the research, clinical development, and eventual commercialization of proprietary drug candidates. Revenue generation is anticipated through partnerships, licensing agreements with larger pharmaceutical companies, and ultimately, sales of its approved therapies. ENB's lead product candidate is ENB-001, a first-in-class small molecule inhibitor of the endothelin B receptor (ETBR).
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- New York City, United States
- Sector
- Biotech & Life Sciences
News
Open roles
ENB Therapeutics in the New York City ecosystem
The ENB Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Remiges Ventures
BioAdvance
Alexandria Venture Investments
Series B and later6 investors entered at this stage
Pipeline Angels
Avestria Ventures- ACAJI Capital
Springboard Enterprises
Accelerate New York Seed Fund
Alexandria LaunchLabs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ENB Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ENB Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

